Trinity Biotech Valuation
| TRIB Stock | USD 0.71 0.00 0.000003% |
Trinity Biotech is undervalued. Trinity Biotech plc has a current Real Value of $2.28 per share. The regular price of the company is $0.70999998. Our model measures the value of Trinity Biotech plc from inspecting the company fundamentals such as Shares Outstanding of 27.52 M, return on equity of -19.13, and Operating Margin of (0.15) % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Trinity Biotech's valuation include:
Price Book 5.1132 | Enterprise Value | Enterprise Value Ebitda (6.06) | Price Sales 0.3142 | Enterprise Value Revenue 1.8442 |
Undervalued
Today
Please note that Trinity Biotech's price fluctuation is extremely dangerous at this time. Calculation of the real value of Trinity Biotech plc is based on 3 months time horizon. Increasing Trinity Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Trinity Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Trinity Stock. However, Trinity Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.71 | Real 2.28 | Target 7.0 | Hype 0.71 | Naive 0.72 |
The real value of Trinity Stock, also known as its intrinsic value, is the underlying worth of Trinity Biotech plc Company, which is reflected in its stock price. It is based on Trinity Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Trinity Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Trinity Biotech plc helps investors to forecast how Trinity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Trinity Biotech more accurately as focusing exclusively on Trinity Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Trinity Biotech's intrinsic value based on its ongoing forecasts of Trinity Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Trinity Biotech's closest peers. If more than one evaluation category is relevant for Trinity Biotech we suggest using both methods to arrive at a better estimate.
Trinity Biotech Cash |
|
Trinity Valuation Trend
Comparing Trinity Biotech's enterprise value against its market capitalization is a good way to estimate the value of Trinity Biotech plc uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Trinity Biotech Total Value Analysis
Trinity Biotech plc is at this time forecasted to have valuation of 109.45 M with market capitalization of 18.58 M, debt of 67.43 M, and cash on hands of 10.01 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Trinity Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
109.45 M | 18.58 M | 67.43 M | 10.01 M |
Trinity Biotech Investor Information
About 12.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 1.3. Trinity Biotech plc recorded a loss per share of 2.25. The entity last dividend was issued on the 5th of June 2015. The firm had 1:5 split on the 23rd of February 2024. Trinity Biotech plc may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Trinity Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Trinity Biotech has an asset utilization ratio of 95.62 percent. This suggests that the Company is making $0.96 for each dollar of assets. An increasing asset utilization means that Trinity Biotech plc is more efficient with each dollar of assets it utilizes for everyday operations.Trinity Biotech Ownership Allocation
Trinity Biotech plc shows a total of 27.52 Million outstanding shares. Trinity Biotech plc has 12.39 % of its outstanding shares held by insiders and 14.6 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Trinity Biotech Profitability Analysis
The company reported the previous year's revenue of 56.83 M. Net Loss for the year was (24.02 M) with profit before overhead, payroll, taxes, and interest of 21.13 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Trinity Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Trinity Biotech and how it compares across the competition.
About Trinity Biotech Valuation
The stock valuation mechanism determines Trinity Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of Trinity Biotech. We calculate exposure to Trinity Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Trinity Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 22.4 M | 35.1 M | |
| Pretax Profit Margin | (0.58) | (0.56) | |
| Operating Profit Margin | (0.43) | (0.41) | |
| Net Loss | (0.38) | (0.36) | |
| Gross Profit Margin | 0.31 | 0.33 |
Trinity Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 153.1 M | |
| Quarterly Earnings Growth Y O Y | -0.773 |
Trinity Biotech Current Valuation Indicators
Valuation refers to the process of determining the present value of Trinity Biotech plc and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Trinity we look at many different elements of the entity such as Trinity's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Trinity Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Trinity Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Trinity Biotech's worth.Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |